Last Updated on 2026 年 3 月 18 日 by 総合編集組
Taiwan Diabetes Landscape in 2025: Rising Prevalence, Early Onset Trends, and Breakthrough Therapies Offering Hope
Taiwan faces a significant public health challenge with diabetes, as the number of diagnosed patients has surpassed 2.5 million, reflecting broader lifestyle and demographic shifts.
Recent data from national health surveys and international reports, including the International Diabetes Federation (IDF) Diabetes Atlas 2025 edition, indicate that the age-standardized prevalence of diabetes among adults aged 20-79 stands at approximately 10.7%, with total cases reaching around 2.598 million. Earlier domestic estimates placed the figure between 2.18 million and 2.56 million, with annual new diagnoses averaging about 180,000 cases—equivalent to roughly 500 new patients daily entering the healthcare system.
Gender differences show a slightly higher rate among men at around 11.4%, compared to 10.0% in women. Among those aged 65 and older, prevalence exceeds 20%, highlighting the impact of an aging society. Type 2 diabetes dominates, accounting for about 99.5% of cases, while Type 1 remains rare at roughly 0.5% (approximately 12,000 individuals).
A particularly concerning development is the marked shift toward earlier onset. Cases among individuals under 40 have surged by about 25% in recent years, and more than 20% of patients now receive diagnosis before age 50. This “younger-onset” pattern deviates from traditional views of diabetes as primarily an elderly condition. Key contributing factors include the widespread popularity of high-sugar beverages—especially Taiwan’s signature hand-shaken drinks, where nearly all full-sugar versions exceed WHO recommended sugar limits—combined with frequent eating out, sedentary digital lifestyles, and insufficient physical activity. Such habits create an environment conducive to early metabolic disturbances, leading to longer disease duration and heightened risk of complications during prime working years, which could strain national productivity and healthcare budgets over time.
At the opposite end of the spectrum, more than half of patients are aged 65 or above, often dealing with multiple comorbidities. Cardiovascular disease affects about 26% of this group, with stroke risk elevated 2 to 4 times compared to the general population. Taiwan, long known for high rates of end-stage kidney disease requiring dialysis, attributes much of this burden to diabetes as the leading cause. The proportion of diabetic patients with chronic kidney disease rose from 13% in 2014 to 28% by 2019. Notably, cancer has overtaken cardiovascular issues as the top cause of death among diabetic individuals, linked to chronic hyperinsulinemia and systemic inflammation.
Treatment paradigms have evolved dramatically from simple glycemic control to comprehensive organ protection and weight management. A standout advancement is tirzepatide (brand name Mounjaro in many markets, locally known as 猛健樂), a dual GIP/GLP-1 receptor agonist approved by Taiwan’s TFDA in April 2023 for Type 2 diabetes and expanded in 2025 to include weight management in adults with comorbidities. By simultaneously targeting GIP and GLP-1 pathways, it enhances post-meal insulin secretion, slows gastric emptying, suppresses appetite signals in the hypothalamus, and improves insulin sensitivity. Clinical trials (SURPASS series) demonstrate superior HbA1c reductions of 1.7% to 2.4% compared to single GLP-1 agents or basal insulin. Weight loss averages 15% to 20% over 72 weeks, making it one of the most potent metabolic agents available. Administered as a once-weekly subcutaneous injection, it offers convenience for many patients.
For those averse to injections, oral semaglutide (Rybelsus) has been available in Taiwan since 2022. It requires strict administration—taken on an empty stomach in the morning with no more than 120 mL of water, followed by 30 minutes without food or drink—to optimize absorption. Monthly costs typically range from NT$5,000 to NT$13,000 as it remains self-pay in most cases. Higher-dose oral formulations, such as oral Wegovy tablets (25 mg or above), received U.S. FDA approval by late 2025 and are expected to launch in early 2026, showing up to 16.6% weight reduction in trials. Taiwan’s adoption timeline will depend on local regulatory review.
SGLT2 inhibitors (e.g., canagliflozin, empagliflozin) continue to play a central role in cardiorenal protection. By blocking renal glucose reabsorption, they excrete about 87 grams of glucose daily via urine, while providing osmotic diuresis and natriuresis that reduce glomerular pressure. Landmark studies like CREDENCE confirm a roughly 30% reduction in dialysis risk. Current guidelines prioritize these agents as first- or second-line options for patients with chronic kidney disease (CKD) or heart failure (HF).
A major policy milestone occurred on March 1, 2025, when Taiwan’s National Health Insurance Administration (NHIA) significantly broadened reimbursement for SGLT2 inhibitors, benefiting nearly 200,000 additional patients with an estimated NT$1.6 billion in new annual funding. Eligibility now includes CKD patients with eGFR 25–60 mL/min/1.73m² and those with HF and LVEF 41%–49%, excluding only those already on dialysis (eGFR <15). This preventive approach aims to delay dialysis onset—potentially by decades in early-stage cases—and alleviate Taiwan’s longstanding “dialysis nation” burden.
Continuous glucose monitoring (CGM) and insulin pumps are also seeing expanded access. By late 2025, NHIA plans to include pregnant women with Type 2 or gestational diabetes, shorten monitoring intervals for Type 1 patients to monthly, and explore primary care prescribing to improve accessibility and reduce hospital visits.
Digital tools enhance daily management. Platforms like Health2Sync allow users to log glucose, diet, and exercise while providing AI-driven dose titration alerts. Studies show sustained use over six months can lower HbA1c by an average of 2.0%, strengthening patient-provider collaboration.
Updated clinical guidelines (aligned with 2024 ADA standards) promote person-centered language to reduce stigma, early CGM or automated insulin delivery for Type 1 at diagnosis, and priority use of cardiorenal-protective drugs regardless of baseline glucose in high-risk cases. Additional recommendations cover bone density screening and vaccinations (RSV, COVID-19) for seniors aged 65+.
Taiwan’s Diabetes Shared Care Network and Pay-for-Performance (P4P) program have improved quality metrics from 2005 to 2020: HbA1c testing rose from 92.2% to 98.2%, lipid checks from 52.8% to 89.5%, urine albumin from 31.0% to 68.2%, and retinal exams from 15.6% to 45.5%. Gaps remain in cross-specialty referrals (e.g., ophthalmology, nephrology), but overall progress is encouraging.
To combat rising youth cases, advocates push for nationwide sugar-reduction measures: sugar taxes on beverages (inspired by successes in the UK and South Africa, where youth incidence fell 16%), front-of-pack warning labels, and stricter school-perimeter restrictions on sugary foods, alongside enhanced metabolic education for children and teens.
In summary, while Taiwan grapples with increasing prevalence driven by aging and modern lifestyles, innovative therapies like tirzepatide, expanded SGLT2 access, digital monitoring, and policy reforms signal a shift toward precision, prevention, and holistic care. Early screening combined with societal sugar-reduction efforts could mitigate long-term impacts on workforce health and national healthcare expenditure, fostering a more sustainable future for millions living with diabetes.
